Abstract
Carcinoma of the pancreas is the fourth leading cause of cancer death in the Western world [1]. Diabetes mellitus, high-fat diets, and tobacco smoking have been implicated as predisposing factors [2]. Ethanol consumption and pancreatitis may also be risk factors [2]. The 1-year overall survival rate in patients with pancreatic cancer is only 12% [3]. Three observations suggest that this malignancy will be an even more serious problem in the industrialized countries than it is today: (a) the incidence of pancreatic cancer increases dramatically after the fifth decade of life, and the general population in these countries is aging; (b) the incidence of diabetes in this population is increasing, and advances in the care of diabetic patients have led to an increase in their longevity; (c) the consumption of fat, alcohol, and tobacco is not abating. In view of the high mortality rate in patients with pancreatic cancer, there is an urgent need to improve the therapeutic options that are available for treating this disorder.
This study was supported by Public Health Service Grant CA-40162, awarded by the National Cancer Institute
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Wills JA (1989) Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 9:1027–1032
Cubilla AL, Fitzgerald PJ (1985) Cancer of the exocrine pancreas: the pathological aspects. CA 35:2–35
Gudjonsson B, Livstone E, Spiro H (1978) Cancer of the pancreas: diagnostic accuracy and survival studies. Cancer 42:2494–2506
Tepper J, Nardi G, Suite H (1976) Carcinoma of the pancreas: review of MGH experience from 1963–1973. Cancer 37:1519–1524
Levine G, Remine WH, Hermann RE, Schein PS, Cohn I (1978) Cancer of the pancreas. Am J Surg 135:185–191
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554
Korc M, Meltzer P, Trent J (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 83:5141–5144
Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor a in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84:7567–7570
Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, Shizume K (1990) Insulin-like growth factor I and transforming growth factor d as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 50:103–107
Beauchamp RD, Lyons RM, Yang EY, Coffey RJ Jr, Moses HL (1990) Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 5:369–380
Moriai T, Takebe T, Makino I, Ishii K (1989) Intratumoral treatment of pancreatic cancer with mitomycin-C adsorbed to activated carbon particles. Anticancer Res 9:1799–1804
Smith FP, Hoth DF, Levin BL et al. (1980) 5-Fluorouracil, Adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014
Moertel CG, Rubin J, O’Connell MJ et al. (1986) A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 4:1053
Pousetta A, Fernstad R, Haggmark A, Skoldefors H, Theve NO, Carlstrom K (1988) The estrogen binding protein in human pancreas: concentrations in subcellular fractions of normal pancreatic tissue, in duodenal juice during pancreatic stimulation and in peripheral serum in normal and pathological conditions. J Steroid Biochem 29:423–427
Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B (1990) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77:725–730
Klijn JGM, Hoff AM, Planting ASTh, Verweij J, Kok T, Lamberts SWJ, portengen H, Foekens J A (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627–630
The Gastrointestinal Tumor Study Group (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48:1705–1710
Ozaki H, Hojo K, Kato H, Kinoshita T, Egawa S, Kishi K (1988) Multidisciplinary treatment for resectable pancreatic cancer. Int J Pancreatol 3:249–260
Colacchio TA, Coughlin C, Taylor J, Douple E, Ryan T, Crichlow RW (1990) Intraoperative radiation therapy and hyperthermia. Arch Surg 125:370–375
Raitano AB, Scuderi P, Korc M (1990) Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 5:267–277
Schmiegel WH, Caeser J, Kalthoff H, Greten H, Schreiber HW, Thiele HG (1988) Antiproliferative effects exerted by recombinant tumor necrosis factor-α (rTNF-α) and interferon-γ (rlFN-γ) on human pancreatic tumor cell lines. Pancreas 3:180–188
Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD Jr (1990) Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery 108:919–929
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Korc, M. (1993). Conventional Treatment of Pancreatic Cancer. In: Beger, H.G., Büchler, M., Malfertheiner, P. (eds) Standards in Pancreatic Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77437-9_65
Download citation
DOI: https://doi.org/10.1007/978-3-642-77437-9_65
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77439-3
Online ISBN: 978-3-642-77437-9
eBook Packages: Springer Book Archive